AI Article Synopsis

  • The study focuses on the IMPACT intervention, which aimed to enhance patient recruitment in cancer treatment clinical trials by providing onsite navigators and financial reimbursements for out-of-pocket expenses.
  • The analysis compared patient enrollment data from January 2016 to March 2020, revealing an average of 69 monthly enrollments, with a notable increase after implementing the IMPACT intervention—around 1 additional patient per month, particularly in late-phase trials.
  • Results indicate that addressing financial barriers and providing support can significantly accelerate patient accrual in clinical trials, highlighting the need for further research on optimizing these strategies.

Article Abstract

Background: Cancer treatment clinical trials face major challenges with patient recruitment. Strategies to address patient indirect costs associated with clinical trial participation may accelerate accrual overall. The current study examined the effect of the IMproving Patient Access to Clinical Trials (IMPACT) intervention on patient accrual to cancer treatment clinical trials at an academic medical center. The IMPACT intervention was an onsite patient navigator combined with a financial reimbursement program to address patient out of pocket costs and began on September 2018.

Methods: This analysis measured frequency of patient enrollment in cancer treatment clinical trials and available cancer treatment clinical trials per month between January 1, 2016 and March 31, 2020. An interrupted time-series analysis (ITSA) was conducted to estimate changes in patient enrollment attributable to the IMPACT intervention.

Results: During the study period, a mean of 69 patients enrolled in clinical trials per month (standard deviation (SD = 13), with 27 (SD = 7) in early phase vs 41 (SD = 12) in late phase clinical trials. The number of available clinical trials per month was 51 (SD = 2) overall, with 23 (SD = 1) in early phase vs 28 (SD = 1) in late phase context. A total of 3470 patients were enrolled in cancer treatment clinical trials during the evaluated time period, the majority of whom were men (1895, 55 %) and racially white (2267, 65 %). A statistically significant increase in the number of patients accrued as compared to the pre-intervention trend was observed; with approximately 1 additional patient accrued per month, with a larger effect on increase patient accrual for late phase clinical trials.

Discussion: This study observed that the IMPACT intervention accelerated clinical trial recruitment, especially among late phase clinical trials. Future research will examine strategies to leverage this infrastructure to optimize recruitment among underrepresented patients.

Policy Summary: To improve clinical trial recruitment and ensure that trial results are representative of a diverse population it is critical for health policies consider patient out-of-pocket costs and potential reimbursement to alleviate financial burden associated with clinical trial participation. Furthermore, policies for facilitating clinical trial recruitment and participant retention should budget for and incorporate a navigation component to assist patients who may not be familiar with the healthcare system and available financial assistance.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcpo.2021.100305DOI Listing

Publication Analysis

Top Keywords

clinical trials
40
clinical trial
24
cancer treatment
20
treatment clinical
20
clinical
17
trial recruitment
16
late phase
16
patient
12
impact intervention
12
trials month
12

Similar Publications

We previously documented successful resolution of skeletal and dental disease in the infantile and late-onset murine models of hypophosphatasia (HPP), with a single injection of an adeno-associated serotype 8 vector encoding mineral-targeted TNAP (AAV8-TNAP-D10). Here, we conducted dosing studies in both HPP mouse models. A single escalating dose from 4x108 up to 4x1010 (vg/b) was intramuscularly injected into 4-day-old Alpl-/- mice (an infantile HPP model) and a single dose from 4x106 up to 4x109 (vg/b) was administered to 8-week-old AlplPrx1/Prx1 mice (a late-onset HPP model).

View Article and Find Full Text PDF

Structural and Functional Glycosylation of the Abdala COVID-19 Vaccine.

Glycobiology

January 2025

Department of Biochemistry, Dorothy Crowfoot Hodgkin Building, University of Oxford, South Parks Road, OX1 3QU, United Kingdom.

Abdala is a COVID-19 vaccine produced in Pichia pastoris and is based on the receptor-binding domain (RBD) of the SARS-CoV-2 spike. Abdala is currently approved for use in multiple countries with clinical trials confirming its safety and efficacy in preventing severe illness and death. Although P.

View Article and Find Full Text PDF

Around one-quarter of all patients undergoing cardiac procedures, particularly those on cardiopulmonary bypass, develop cardiac surgery-associated acute kidney injury (CSA-AKI). This complication increases the risk of several serious morbidities and of mortality, representing a significant burden for both patients and the healthcare system. Patients with diminished kidney function before surgery, such as those with chronic kidney disease, are at heightened risk of developing CSA-AKI and have poorer outcomes than patients without preexisting kidney injury who develop CSA-AKI.

View Article and Find Full Text PDF
Article Synopsis
  • Lung cancer has the highest incidence and mortality rates globally, making effective post-surgical mental health support crucial due to associated challenges like anxiety and depression.
  • Traditional Chinese medicine shows promise in improving psychological well-being and physical symptoms after lung cancer surgery, but its effectiveness specifically for mental function recovery needs investigation.
  • The study will systematically review various databases for randomized controlled trials focusing on depression and anxiety after lung cancer surgery, assessing data quality and outcomes using established evaluation tools.
View Article and Find Full Text PDF

Background: Insomnia is the most common sleep disturbance among cancer patients undergoing active treatment. If untreated, it is associated with significant physical and psychological health consequences. Prior efforts to determine insomnia prevalence and correlates have primarily assessed patients in clinical trials, in limited disease groups, and excluding important patient subgroups.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!